Interdisciplinary Program in Neuroscience, Georgetown University, School of Medicine, Washington, DC, USA.
Ann Neurol. 2012 Sep;72(3):363-72. doi: 10.1002/ana.23600. Epub 2012 May 11.
Drug exposure during critical periods of brain development may adversely affect nervous system function, posing a challenge for treating infants. This is of particular concern for treating neonatal seizures, as early life exposure to drugs such as phenobarbital is associated with adverse neurological outcomes in patients and induction of neuronal apoptosis in animal models. The functional significance of the preclinical neurotoxicity has been questioned due to the absence of evidence for functional impairment associated with drug-induced developmental apoptosis.
We used patch-clamp recordings to examine functional synaptic maturation in striatal medium spiny neurons from neonatal rats exposed to antiepileptic drugs with proapoptotic action (phenobarbital, phenytoin, lamotrigine) and without proapoptotic action (levetiracetam). Phenobarbital-exposed rats were also assessed for reversal learning at weaning.
Recordings from control animals revealed increased inhibitory and excitatory synaptic connectivity between postnatal day (P)10 and P18. This maturation was absent in rats exposed at P7 to a single dose of phenobarbital, phenytoin, or lamotrigine. Additionally, phenobarbital exposure impaired striatal-mediated behavior on P25. Neuroprotective pretreatment with melatonin, which prevents drug-induced neurodevelopmental apoptosis, prevented the drug-induced disruption in maturation. Levetiracetam was found not to disrupt synaptic development.
Our results provide the first evidence that exposure to antiepileptic drugs during a sensitive postnatal period impairs physiological maturation of synapses in neurons that survive the initial drug insult. These findings suggest a mechanism by which early life exposure to antiepileptic drugs can impact cognitive and behavioral outcomes, underscoring the need to identify therapies that control seizures without compromising synaptic maturation.
在大脑发育的关键时期接触药物可能会对神经系统功能产生不良影响,这对治疗婴儿构成了挑战。这对于治疗新生儿癫痫尤其令人关注,因为婴儿早期接触苯巴比妥等药物与患者的不良神经结局以及动物模型中诱导神经元凋亡有关。由于没有证据表明与药物诱导的发育性细胞凋亡相关的功能损伤,因此临床前神经毒性的功能意义受到质疑。
我们使用膜片钳记录技术检查了来自暴露于具有促凋亡作用的抗癫痫药物(苯巴比妥、苯妥英、拉莫三嗪)和无促凋亡作用的抗癫痫药物(左乙拉西坦)的新生大鼠纹状体中型多棘神经元中的功能性突触成熟情况。还在断奶时评估了暴露于苯巴比妥的大鼠的反转学习能力。
来自对照动物的记录显示,出生后第 10 天至第 18 天之间,抑制性和兴奋性突触连接增加。在 P7 时单次暴露于苯巴比妥、苯妥英或拉莫三嗪的大鼠中,这种成熟不存在。此外,苯巴比妥暴露会损害 P25 时的纹状体介导的行为。预防性给予褪黑素(一种可预防药物诱导的神经发育性细胞凋亡的物质)可防止药物引起的成熟障碍。发现左乙拉西坦不会破坏突触发育。
我们的研究结果首次提供了证据,表明在敏感的产后时期接触抗癫痫药物会损害存活下来的神经元中突触的生理成熟。这些发现表明,婴儿早期接触抗癫痫药物会影响认知和行为结局的一种机制,强调了需要确定既能控制癫痫发作又不会损害突触成熟的治疗方法。